Alkami price target lowered to $25 from $30 at Barclays

Barclays analyst Saket Kalia lowered the firm’s price target on Alkami (ALKT) to $25 from $30 and keeps an Equal Weight rating on the shares. The company reported annual recurring revenue slightly below estimates due to timing of new user implementations, which by shifting later in the year leads to less in-year revenue, the analyst tells investors in a research note.